Trial · NCT07893652
Severe Pediatric Respiratory Syncytial Virus Infections Occurring in the Era of Antiviral Prophylaxis
NCT07893652, Not yet recruiting, Assistance Publique - Hôpitaux de Paris
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Severe Pediatric Respiratory Syncytial Virus Infections Occurring in the Era of Antiviral Prophylaxis. Trials, record NCT07893652. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07893652
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Severe Pediatric Respiratory Syncytial Virus Infections Occurring in the Era of Antiviral Prophylaxis
- NCT number
- NCT07893652
- Status
- Not yet recruiting
- Enrollment
- 300 participants, estimated
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Conditions
- Children <24 Months Hospitalized for RSV-related Lower Respiratory Tract Infection
- Interventions
- Prior exposure to prophylactic treatment with Abrysvo or nirsevimab/clesrovimab, Non-exposure to prior prophylactic treatment
- First posted
- 2026-10-26
- Last updated
- 2026-10-26
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | RSV variants with reduced sensitivity to prophylaxis | Day0/At inclusion | Detection of virological variants with decreased sensitivity to the prophylaxis previously administered (nirsevimab/clesrovimab and/or Abrysvo), performed by sequencing the full-length RSV genome to detect any polymorphisms and/or resistance associated mutations in the F protein |
| Secondary | RSV variants with reduced sensitivity to nirsevimab/clesrovimab according to age at hospitalization | Day 0 | Detection among children exposed to nirsevimab/clesrovimab before 12 months of age and assessment of RSV harboring polymorphisms or resistance-associated substitutions conferring decreased susceptibility to nirsevimab/clesrovimab in those hospitalized for RSV LRTI during their 1st year of life versus those hospitalized during their 2nd year of life |
| Secondary | Immunological characteristics of children hospitalized with RSV LRTI | Day 0 | Detection of the following immunological characteristics: * identification of a primary immune deficiency (previously undiagnosed in the participants), by whole exome sequencing * detection of auto-antibodies neutralizing type I IFNs in serum, by a luciferase reporter assay and multiplex detection assays |
| Secondary | Mucosal immunity of children hospitalized with RSV LRTI | Day 0 | Assessment of mucosal immunity (detection in saliva swabs of IgG or SIgA anti-RSV response (protein F), and correlation with functional neutralizing anti-RSV responses (RSV A and B strain)) |
| Secondary | Viral kinetics | Day 0 and 7 +/-2 days | Evaluation of the kinetics of RSV RNA in nasal swab at inclusion and day 7+/-2 (for patients still hospitalized), using qPCR |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07893652
GET https://conductscience.org/api/trials/v1/NCT07893652/registered